23:07 , Sep 19, 2018 |  BC Extra  |  Company News

Management tracks: GSK adds Corsico, Enzmann to chair CHMP

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) hired Chris Corsico, CMO of Boehringer Ingelheim GmbH (Ingelheim, Germany), to lead all development activities for the pharma. As SVP development, Corsico will be based at GSK’s R&D hub in Stevenage,...
23:21 , Jan 9, 2018 |  BC Extra  |  Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
22:23 , Apr 6, 2017 |  BC Innovations  |  Targets & Mechanisms

Competing for growth

With little in the clinical pipeline for achondroplasia beyond BioMarin Pharmaceutical Inc. ’s late-stage vosoritide, startups Therachon AG and BioClin Therapeutics Inc. are rethinking how to tackle the disease. By targeting FGFR3 directly, the two...
20:15 , Mar 24, 2017 |  BC Week In Review  |  Financial News

BioClin completes venture financing

On March 22, antibody company BioClin Therapeutics Inc. (San Ramon, Calif.) raised $30 million in a series B round led by new investors Sofinnova Ventures and Ysios Capital. Existing investors HealthCap, LSP and Tekla Capital...
21:00 , Mar 22, 2017 |  BC Extra  |  Financial News

BioClin raises $30M in series B

Antibody company BioClin Therapeutics Inc. (San Ramon, Calif.) raised $30 million in a series B round led by new investors Sofinnova Ventures and Ysios Capital. Existing investors HealthCap, LSP and Tekla Capital Management also participated....
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

B-701: Phase II started

BioClin began a double-blind, placebo-controlled, U.S. Phase II trial to compare 25 mg/kg IV B-701 with docetaxel on day 1 of each 21-day cycle vs. docetaxel alone in about 211 patients with stage IV disease...